deltatrials
Terminated OBSERVATIONAL NCT04923802

Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION) (MOTIVATION)

A Multicenter Prospective Observational Study of Non-small Cell Lung Cancer Patients for Development and Validation of Computational Method for Multi-omics-based Neoantigen Prediction and Biomarkers for Immunotherapy Response Evaluation

Sponsor: Affiliated Cancer Hospital of Shantou University Medical College

Conditions Biomarker Neoantigen Next-generation Sequencing Non-small Cell Lung Cancer
Updated 8 times since 2021 Last updated: Mar 6, 2024 Started: Jun 24, 2021 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Unable to recruit sufficient numbers of patients

A observational or N/A phase clinical study on Biomarker and Neoantigen, this trial is terminated or withdrawn. The trial is conducted by Affiliated Cancer Hospital of Shantou University Medical College and has accumulated 8 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2021 – ~Feb 2023 · 17 months · monthly snapshotRecruiting~Feb 2023 – ~Apr 2024 · 14 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshotTerminated~Aug 2025 – ~Dec 2025 · 4 months · monthly snapshot~Dec 2025 – ~Mar 2026 · 3 months · monthly snapshot~Mar 2026 – present · 5 months · monthly snapshot

Change History

8 versions recorded

  1. Mar 2026 — Present [monthly]

    Terminated

  2. Dec 2025 — Mar 2026 [monthly]

    Terminated

  3. Aug 2025 — Dec 2025 [monthly]

    Terminated

  4. Sep 2024 — Aug 2025 [monthly]

    Terminated

  5. Jul 2024 — Sep 2024 [monthly]

    Terminated

▶ Show 3 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Terminated

    Status: Recruiting → Terminated

  2. Feb 2023 — Apr 2024 [monthly]

    Recruiting

  3. Sep 2021 — Feb 2023 [monthly]

    Recruiting

    First recorded

Jun 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Affiliated Cancer Hospital of Shantou University Medical College
  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
  • First Affiliated Hospital of Wenzhou Medical University
  • First Hospital of China Medical University
  • Fujian Provincial Hospital
  • GeneCast Biotechnology Co., Ltd.
  • Guizhou Provincial People's Hospital
  • Peking University Shenzhen Hospital
  • People's Hospital of Chongqing
  • Renmin Hospital of Wuhan University
  • Shanghai Chest Hospital
  • Shanghai Pulmonary Hospital, Shanghai, China
  • Shanxi Province Cancer Hospital
  • Sichuan Cancer Hospital and Research Institute
  • Southwest Hospital, China
  • The Affiliated Hospital Of Southwest Medical University
  • The First Affiliated Hospital of Zhengzhou University
  • The Second Affiliated Hospital of Kunming Medical University
  • The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
  • Tongji Hospital
  • Wuhan University
  • Xinqiao Hospital of Chongqing
Data source: GeneCast Biotechnology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations